Tulsa’s Ascension St. John Clinical Research Institute Joints ACTIV-2 Program Testing Monoclonal Antibodies Against COVID-19

Tulsa’s Ascension St. John Clinical Research Institute Joints ACIV-2 Program Testing Monoclonal Antibodies Against COVID--19

Ascension St. John clinical research institute joined the ACTIV-2 clinical trial to investigate two different antibodies to treat patients very early in the illness. According to infectious disease doctor Anuj Malik with that Tulsa, Oklahoma-based health care system, the moment someone feels like they have a standard annual sinus infection, they should think again and get a COVID-19 test and consider a potential clinical trial, including the ACTIV-2 study that in this case centers on monoclonal antibodies covered by TrialSite—BRII-196 and BRII-198 developed by Brii Biosciences. Each one of these investigational products target different elements of the novel coronavirus and the hope is that both therapeutics could rapidly not only improve efficacy but also lessen the likelihood that the pathogen can form a resistance to treatment.

Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership, reported Shae Rozzi with Fox23 News reports on this national study’s local presence in Tulsa, Oklahoma.  Sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), the actual trial is conducted by the trial site network known as the AIDS Clinical Trials Group (ACTG).

Among over 90 trial sites in this NIAID-sponsored clinical trial, the investigators hope that this pair of monoclonal antibodies can speed recovery and actually serve to lower the risk of infection moving forward.

The Research Center

Part of the Ascension health system, Ascension St. John clinical research institute contributes to medical science and offers innovative medicines and therapies to patients. St. John Clinical Research coordinates and conducts clinical trials by providing investigators with efficient infrastructure, committed research staff and operational expertise for the conduct of FDA/GcP-based clinical research. 

Here, a group of full-time registered nurse research coordinators commit 100 percent of their time to research, while clinical staff are specifically trained to perform research procedures and collect data as required by any particular study protocol as well as in alignment with federal, state and local regulations and guidelines. Presently, the health system research institute has 22 active clinical trials across a range of therapeutic area. For a full description of services, follow the link to the institute’s website

Ascension Health

Ascension, founded as a nonprofit Catholic system, is one of the largest healthcare system in the United States, ranking second in the nation by number of hospitals by 2019. The largest Catholic system by 2018, the organization employed about 165,000 employees with 151 hospitals and $22.6 billion in revenue. The system has 40,000 providers, 28,000 available beds, and has 3 million emergency visits a year, according to its recent “Facts and Stats.”  

Local Research/investigator

Dr. Anuj Malik

Call to Action: For those individuals living in the Tulsa, OK region that may have a loved one ill with COVID-19: consider this clinical trial at the Ascension St. John clinical research institute. Visit www.ACTIV-2.org or call 918-744-3463 in the Tulsa region.